Article Text

PDF
Fifteen-minute consultation: assessment, surveillance and management of hemihypertrophy
  1. Catherine Mark1,
  2. Caroline Hart2,
  3. Anthony McCarthy3,
  4. Andrew Thompson3,4
  1. 1 MRC centre for medical mycology, Aberdeen Royal Infirmary (Foresterhill Hospital), Aberdeen, Scotland, UK
  2. 2 Department of Paediatrics, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, UK
  3. 3 Children’s Haematology Unit, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, UK
  4. 4 General Paediatrics, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, UK
  1. Correspondence to Catherine Mark, MRC centre for medical mycology, Aberdeen Royal Informary (Foresterhill), Aberdeen AB25 2ZN, UK; catherinemark{at}hotmail.co.uk

Abstract

This article aims to provide a structured and concise guide for the general paediatrician managing a child with hemihypertrophy. Hemihypertrophy is a relatively uncommon condition. The significance is that a proportion of those affected are at risk of developing malignancies in childhood. For these children regular surveillance is required. We have outlined how one might assess and investigate a child presenting with hemihypertrophy. We have also formulated a practicable surveillance strategy which is in line with the current Royal College of Paediatrics and Child Health (RCPCH) guideline ‘Wilms’ tumour surveillance in at-risk children’.

  • hemihypertrophy
  • childhood
  • paediatric practice
  • malignancy

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.